Interdisciplinary training in pharmacological sciences

分子药理学和生理学的研究生课程规模很小，而且非常多样化 该计划具有一套强大的课程和活动，以及广泛的指导机制。 项目的领导是由三名有成就的MPI组成的小组，并相互补充 确保对项目进行有效监督的实力和专业知识。请求是4个 每年T32个名额；参加该计划的学生总数为20人。该培训计划在 “药理学跨学科培训”将取代我们目前的NIGMS 药理学T32,2021年6月结束。我们节目中的培训重点是基础 药理学原理、严密性和重复性以及尖端的定量方法。我们的 学员参加许多促进互动、协作和专业的活动 发展。在这里，我们提出了一些新的课程倡议，专业人士 发展、项目监督和招聘。我们最近正在开发的一项创新计划 该计划包括在辉瑞制药公司设立暑期实习岗位 这些实习将给我们的实习生提供独特的机会，亲身体验 在制药公司的科学环境中，为他们的未来做出明智的决定 事业。我们目前的招生和招聘做法产生了很高比例的 来自弱势群体和代表性不足群体的学生(在过去5年中，47% 代表不足的少数群体加上7%的残疾人)，并100%保留了这些 过去15年参加该项目的学生(该项目的总体保留率为95%)。 学生的职业生涯结果很好，52%的学生留在了学术界 (25%的教职员工，27%的博士后)经常在顶尖学府工作，约25%的人是 制药或生物技术公司，其余的在各种科学和 与医学相关的职业。因此，我们的计划一直在培养高度多样化的学生群体 他们在不同的科学领域取得了成功；我们在我们的 T32的应用将进一步强化我们独特的项目，提高培训质量。

The Graduate Program in Molecular Pharmacology & Physiology is a small and very diverse program with a strong set of courses and activities, as well as extensive mentoring mechanisms. Leadership of the program is by a group of three accomplished MPIs with complementary strengths and expertise that guarantee effective oversight of the program. The request is for 4 T32 slots per year; the total number of students in the program is 20. This training program in "Interdisciplinary Training in Pharmacological Sciences" will replace our current NIGMS pharmacology T32, ending in June of 2021. The training in our program focuses on fundamental principles of pharmacology, rigor and reproducibility, and cutting-edge quantitative methods. Our trainees participate in many activities that promote interaction, collaboration and professional development. Here we propose a number of new initiatives in the curriculum, professional development, program oversight and recruitment. A recent innovative initiative we are developing in the program is the establishment of summer internships at Pfizer pharmaceutical company labs; these internships will give our trainees the unique opportunity to experience first-hand the scientific environment in a pharmaceutical company and make informed decisions for their future careers. Our current admissions and recruitment practices have yielded a high percentage of students from disadvantaged and underrepresented groups (in the last 5 years, 47% underrepresented minorities plus 7% disabled), and there has been 100% retention of these students in the program during the last 15 years (retention for the program in general is 95%). The career outcomes of the students are excellent, with 52% of students staying in academia (25% faculty, 27% currently postdocs) often at top institutions, about 25% as scientists in pharmaceutical or biotechnology companies, and the remainder in a variety of science and medicine- related careers. Thus, our program has been training a highly diverse group of students who have become successful in different areas of science; the new initiatives proposed in our T32 application will further enhance our unique program and improve the quality of the training.